Telix Pharmaceuticals (ASX:TLX) has resubmitted its NDA for TLX101-Px, a PET imaging agent for brain cancer. The company reported that Part 1 of the global Phase 3 ProstACT study for TLX591-Tx in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results